Validation of an 18F-labeled biphenylalkyne as a positron emission tomography imaging agent for β-amyloid plaques

Nuclear Medicine and Biology

Volumn 36, Issue 4, 2009, Pages 411-417

  Wey, Shiaw Pyng ^a,b   Weng, Chi Chang ^a   Lin, Kun Ju ^a,b   Yao, Cheng Hsiang ^b   Yen, Tzu Chen ^a,b   Kung, Hank F ^c   Skovronsky, Daniel ^d   Kung, Mei Ping ^a,c  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

Alzheimer's disease; Autoradiograph; Brain imaging; In vitro binding; Radiofluorination

Indexed keywords

6 IODO 2 (4' DIMETHYLAMINO )PHENYLIMIDAZO[1,2 A]PYRIDINE I 125; ALKYNE; AMYLOID BETA PROTEIN; AV 138 F 18; FLUORINE 18; PHOSPHORUS; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN TISSUE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; IN VITRO STUDY; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; WHITE MATTER;

ALKYNES; ALZHEIMER DISEASE; ANILINE COMPOUNDS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ETHYLENE GLYCOLS; FLUORINE RADIOISOTOPES; HUMANS; KINETICS; LIGANDS; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; SENILE PLAQUES; STAINING AND LABELING;

EID: 67349212261     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.01.013     Document Type: Article

References (16)

1. Golde T.E. The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol 15 (2005) 84-87
2. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
3. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004) 306-319
4. Mathis C.A., Klunk W.E., Price J.C., and DeKosky S.T. Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol 62 (2005) 196-200
5. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46 (2003) 2740-2754
6. 11C-Labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol 30 (2003) 565-571
7. 11C]SB-13 PET. Am J Geriatr Psychiatry 12 (2004) 584-595
8. Small G.W. Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease. J Geriatr Psychiatry Neurol 19 (2006) 180-185
9. Shoghi-Jadid K., Barrio J.R., Kepe V., Wu H.M., Small G.W., Phelps M.E., et al. Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization. Nucl Med Biol 32 (2005) 337-351
10. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7 (2008) 129-135
11. 18F-labeled amyloid-imaging agents in Alzheimer's disease patients and healthy elderly controls. J Nucl Med 49 (2008) 34p
12. Buckner R.L., Snyder A.Z., Shannon B.J., LaRossa G., Sachs R., Fotenos A.F., et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25 (2005) 7709-7717
13. Chandra R., Oya S., Kung M.P., Hou C., Jin L.W., and Kung H.F. New diphenylacetylenes as probes for positron emission tomographic imaging of amyloid plaques. J Med Chem 50 (2007) 2415-2423
14. Kung M.P., Hou C., Zhuang Z.P., Skovronsky D., and Kung H.F. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res 1025 (2004) 89-105
15. 18F-Labeled styrylpyridines as PET agents for amyloid plaque imaging. Nucl Med Biol 34 (2007) 89-97
16. Zhang W., Oya S., Kung M.P., Hou C., Maier D.L., and Kung H.F. F-18 PEG stilbenes as PET imaging agents targeting Aβ aggregates in the brain. Nucl Med Biol 32 (2005) 799-809